Dengue fever has surpassed 500 cases in the United States in 2026, following a record-breaking 2024 that saw 3,798 confirmed cases reported to the CDC's ArboNET surveillance system, a 359 percent increase above the 2010 to 2023 annual average. The mosquito primarily responsible for spreading the virus, Aedes aegypti, is now confirmed to be expanding its range northward into states well beyond its traditional subtropical stronghold. And this summer, the window for local transmission risk extends further into the continental United States than it did a decade ago.
Public health authorities, entomologists, and infectious disease specialists are tracking the shift with concern. Dengue is not simply a travel disease any longer for Americans. While the vast majority of cases remain travel-associated, the conditions enabling local transmission are broadening with each passing season.
Why This Matters
Most people who contract dengue experience a flu-like illness and recover fully. But dengue is unusual among mosquito-borne diseases in that a second infection with a different dengue serotype, there are four, can trigger severe hemorrhagic fever. This condition causes the blood vessels to leak, platelets to drop, and in serious cases can lead to organ failure and death. There is currently no approved dengue vaccine recommended for general use in the continental United States, and no specific antiviral treatment.
The cases most visible to U.S. readers are concentrated in Florida, where Miami-Dade County has maintained an active mosquito-borne illness alert through 2026. But the more significant public health story is what is happening further north. A peer-reviewed paper in the CDC's Emerging Infectious Diseases journal documented a seven-week chain of locally acquired dengue transmission in Los Angeles County in 2025, the kind of sustained community spread once considered impossible outside the subtropical south.
What We Know So Far
The 2024 MMWR report on dengue in the United States is the most comprehensive recent picture of the national burden. Of the 3,798 cases reported that year, 97.2 percent were travel-associated, with most acquired in the Caribbean, Central America, or Mexico. But 2.8 percent, approximately 106 cases, were locally acquired, a number that, while small in absolute terms, was significantly higher than in most prior years.
The seasonal pattern is consistent and important: dengue cases peak between July and September, accounting for 41.6 percent of annual cases, according to the same MMWR. That means the current period, mid-summer 2026, is the highest-risk window of the year. Cases in 2026 have already passed 500 as of the brief period so far this year, continuing the upward trend that marked 2024.
Florida reported 1,044 local and travel-associated dengue cases in 2024, more than any other continental state. California followed with 719 cases, driven largely by travel-associated infections in the Los Angeles metro area, though the documented local transmission chain in Los Angeles County has raised the profile of the state as an emerging risk area.
Where the Risk Is Highest
Florida remains the highest-risk state for locally acquired dengue in the continental United States. Miami-Dade County's subtropical climate sustains Aedes aegypti populations year-round, and the county accounts for the large majority of Florida's locally transmitted cases. Hillsborough, Pasco, Manatee, Monroe, Orange, Palm Beach, Broward, Sarasota, and Polk counties in Florida all reported locally acquired cases in 2024. Southern Texas and California's major metro areas present the next tier of risk.
The more notable development is the northward range extension of Aedes aegypti and its close relative Aedes albopictus, commonly called the tiger mosquito. Published research from the University at Albany, released in September 2024, attributed dengue risk expansion in California, Arizona, and the Carolinas to the documented range extension of both species. A 2026 mosquito surveillance report projects continued expansion into previously unaffected northern states, with localized dengue transmission risk expected to grow in new geographies.
In practical terms, residents of Charlotte, Atlanta, Phoenix, Los Angeles, and San Diego now live within the potential range of mosquitoes capable of transmitting dengue. That does not mean dengue cases will inevitably occur in those cities, but the biological conditions are now present in a way they were not a generation ago.
What Doctors and Experts Say
The University of Florida's Emerging Pathogens Institute has noted that while no part of the continental United States is officially classified as endemic for dengue, Florida's health department continues to report locally acquired cases each year, and the risk is no longer limited to its southernmost counties. Researchers at the institute have linked the resurgence of Aedes aegypti in Florida, after a period of near-displacement by Aedes albopictus in the 1990s, to the conditions that have enabled more frequent local transmission since 2009.
The CDC's public health guidance for jurisdictions facing dengue transmission risk emphasizes vector control as the primary intervention when Aedes mosquito populations are high, temperatures and precipitation support mosquito activity, and travel-associated case counts are elevated. All three conditions now apply in multiple U.S. metropolitan areas during the summer months.
Puerto Rico remains the most severely affected U.S. territory, having reported 6,291 dengue cases in 2024, with more than 52 percent of those requiring hospitalization and 13 deaths. A public health emergency remains in effect there.
What the Evidence Shows and What It Does Not
The evidence that dengue risk is expanding in the continental United States is supported by multiple lines of data: CDC ArboNET surveillance showing rising case counts, peer-reviewed entomological research documenting vector range expansion, a confirmed local transmission chain in Los Angeles, and sustained activity in Florida. What remains uncertain is how quickly and how broadly that risk will translate into large-scale local outbreaks outside of southern Florida.
The 2024 case spike was partly driven by historically high global dengue activity, which increases the probability that returning travelers will seed the virus into areas with competent mosquito populations. Whether 2026 continues that trend at the global level will affect how many importation events occur in U.S. cities this summer.
The United States does not have a dengue vaccine currently recommended for general continental use. Dengvaxia, approved only for individuals aged 9 to 16 with prior confirmed dengue infection in U.S. territories including Puerto Rico, is being discontinued, with remaining stock expiring in 2026. No other dengue vaccine has received U.S. FDA approval or CDC recommendation for continental travelers or residents.
Who Faces the Greatest Risk
People at highest risk include residents of southern Florida, especially Miami-Dade County, and individuals who travel to Caribbean nations, Mexico, and Central America, where dengue activity remains common during summer and fall. Travelers to Puerto Rico face an ongoing elevated risk given the active outbreak status there.
Anyone who has already been infected with dengue once, regardless of which serotype, faces a more serious medical risk from a subsequent infection with a different serotype. Older adults, pregnant individuals, and people with underlying health conditions such as diabetes or chronic kidney disease are most likely to experience complications from either primary or secondary infection.
Residents of cities in the Carolinas, Southern California, Arizona, and the Gulf Coast region should be aware that Aedes mosquitoes capable of transmitting dengue are now present in their communities, even if locally acquired transmission remains uncommon.
Symptoms and Warning Signs to Watch For
Dengue symptoms typically appear four to 10 days after a mosquito bite from an infected Aedes mosquito. The classic presentation is a sudden high fever accompanied by severe headache, pain behind the eyes, muscle and joint pain, nausea, vomiting, swollen glands, and a skin rash. The joint and muscle pain can be so severe that dengue is sometimes called breakbone fever.
Most people recover within one to two weeks. Severe dengue, more likely in people experiencing a second infection, can cause bleeding under the skin, gum or nose bleeds, blood in urine or stool, persistent vomiting, abdominal pain, rapid breathing, fatigue, and restlessness. Severe dengue is a medical emergency requiring immediate hospitalization. Anyone with these symptoms who has recently been in a dengue-risk area should seek emergency care immediately.
What You Can Do Now
Use EPA-registered mosquito repellents containing DEET, picaridin, IR3535, oil of lemon eucalyptus, or para-menthane-diol on exposed skin whenever outdoors, particularly during peak mosquito hours from dawn to dusk. Wear long sleeves and pants in areas where Aedes mosquitoes are active. Remove standing water from flowerpots, buckets, bird baths, gutters, and any container that can hold water for more than a week, as Aedes mosquitoes breed in very small amounts of still water.
Travelers planning visits to dengue-risk areas should consult the CDC's destination-specific dengue guidance before departure and report any fever or flu-like illness that develops within two weeks of returning home to a health care provider, with disclosure of travel history.
Anyone experiencing a high fever with severe headache and joint pain within two weeks of returning from a dengue-risk area should seek medical evaluation promptly, as early diagnosis and supportive care improve outcomes.
Cost and Access: What Patients Should Know
There is no specific antiviral treatment for dengue. Management is supportive, meaning rest, fluids, and pain relief with acetaminophen rather than aspirin or ibuprofen, which can worsen bleeding risk. Severe dengue requiring hospitalization is covered under most major health insurance plans. Uninsured patients who need hospital care for severe dengue should contact their county health department about emergency Medicaid enrollment or charity care programs.
Dengue testing through a blood panel is available through most major diagnostic laboratories and hospital systems in areas where the disease is recognized. Clinicians in regions without prior dengue experience may need to specifically request arboviral testing panels.
What Happens Next
The CDC continues to update ArboNET dengue case data throughout the summer. Health departments in Florida, Texas, California, and other at-risk states are maintaining vector surveillance and issuing localized alerts as conditions warrant. Researchers tracking the Aedes aegypti range expansion are expected to publish updated findings before the end of the 2026 season.
MedicalDaily will continue to track dengue activity in the United States through the fall.
The Bottom Line
Dengue is no longer a disease that only travelers returning from the tropics need to worry about. The record 2024 U.S. case count, the documented local transmission in Los Angeles, the sustained risk in Miami-Dade, and the confirmed northward expansion of the Aedes mosquito mean that more Americans than ever are living in areas where local dengue transmission is biologically possible during summer months. Strong mosquito repellent use, standing water elimination, and prompt medical evaluation for fever after potential exposure are the most effective protective steps available right now.
